Drug Profile
Fluticasone propionate hydrofluoroalkane inhalation - GSK
Alternative Names: FLOVENT HFA; Fluticasone propionate HFA; Fluticasone propionate HFA inhalation - GSKLatest Information Update: 08 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Inorganic sulfur compounds; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma
Most Recent Events
- 12 Feb 2019 Chemical structure information added
- 28 Jun 2018 No recent reports of development identified for phase-I development in Asthma(In infants) in USA (Inhalation)
- 28 Aug 2006 Phase-I clinical trials in Asthma (In infants) in USA (Inhalation) (NCT00370097)